

## Chromatin remodeling protein HELLS is upregulated by inactivation of the RB-E2F pathway and is nonessential for osteosarcoma tumorigenesis


## SUPPLEMENTARY MATERIALS




Supplementary Figure 1: Osteosarcoma mouse models display no gender variation. Kaplan–Meier curves showing the survival of osteosarcoma-prone mouse models divided by gender. (A) p53 cKO: Osx-cre;  $p53^{lox/lox}$  (male: n=19; female: n=16). (B) p53/Rb1 DKO: Osx-cre;  $Tp53^{lox/lox}$ ;  $Rb1^{lox/lox}$  (male: n=18; female: n=11). (C) p53/Rb1/E2f1 TKO: Osx-cre;  $p53^{lox/lox}$ ;  $Rb1^{lox/lox}$ 



Supplementary Figure 2: E2F2 or E2F3 knockdown does not affect HELLS protein levels and palbociclib decreases phosphorylated RB. Western blot detection of (A) E2F1, E2F2 and HELLS protein level in osteosarcoma cells transduced with lentivirus containing shRNA against E2F1 (shE2F1) and E2F2 (shE2F2) show no significant change in HELLS expression; (B) E2F3 and HELLS protein level in osteosarcoma cells transduced with lentivirus containing shRNA against E2F3 (shE2F3) show no significant change in HELLS expression, and (C) phosphorylated RB (pRB) in osteosarcoma cell lines after Palbociclib-treated for 24 h show decreased phosphor-RB, Actin used as loading control.





**Supplementary Figure 3: Males present a better prognosis in p53/Hells DKO mice.** Kaplan–Meier curves showing the survival of *Hells*-null osteosarcoma mouse models divided by gender. (**A**) p53/Hells DKO: Osx-cre;  $Tp53^{lox/lox}$ ;  $Hells^{lox/lox}$  (male: n=10; female: n=13). (**B**) Tp53/Rb1/Hells TKO: Osx-cre;  $Tp53^{lox/lox}$ ;  $Hells^{lox/lox}$ ;  $Hells^{lox/lox}$ ;  $Hells^{lox/lox}$  (male: n=10; female: n=12). Mantel-Cox test and Mantel-Haenszel hazard ratio (HR) were used for curve comparisons.